Abstract
The indole alkaloid ibogaine (NIH 10567, Endabuse) is currently being examined for its potential utility in the treatment of cocaine and opioid addiction. However, a clearly defined molecular mechanism of action for ibogaine's putative anti-addictive properties has not been delineated. Radioligand binding assays targeting over 50 distinct neurotransmitter receptors, ion channels, and select second messenger systems were employed to establish a broad in vitro pharmacological profile for ibogaine. These studies revealed that ibogaine interacted with a wide variety of receptors at concentrations of 1–100 µM. These included the mu, delta, kappa, opiate, 5HT2, 5HT3, and muscarinic1 and 2 receptors, and the dopamine, norepinephrine, and serotonin uptake sites. In addition, ibogaine interacted withN-methyl-d-aspartic acid (NMDA) associated ion and sodium ion channels as determined by the inhibition of [3H]MK-801 and [3H]bactrachotoxin A 20-α-benzoate binding (BTX-B), respectively. This broad spectrum of activity may in part be responsible for ibogaine's putative anti-addictive activity.
Similar content being viewed by others
References
Akiyama K, Gee KW, Mosberg HI, Hrudy VJ, Yamamura HI (1985) Characterization of [3]DPDPEN binding to delta opiate receptors in rat brain and neuroblastoglioma hybrid cell line (NG108-15). Proc Natl Acad Sci USA 82:2543–2547
Broderick PA, Phelan FT, Berger SP (1992) Ibogaine alters cocaine-induced biogenic amine and psychostimulant dysfunction but not [3H]GBR-12935 binding to the dopamine transporter protein. NIDA Research Monographic 96. US Government Printing Office, Washington DC
Choi D (1988) Glutamate neurotoxicity and diseases of the neurvous system. Neuron 1:623–634
Coward DM (1992) General pharmacology of clozapine. Br J Psychiatry Suppl 17:5–111
Creveling CR, McNeal ET, Daly JXW, Brown GB (1983) BTX-induced depolarization in [3H]BTX-Δ-20 Benzoate binding in vesicular preparations from guinea pig cerebral cortex: inhibition by local anesthetics. Mol Pharmacol 23:350–358
D'Amato RJ, Largent BL, Snowman AM, Synder SH (1987) Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling multiple sites by [3H]imipramine. J Pharmacol Exp Ther 242:364–371
Deecher DC, Teitler M, Soderlund DM, Bornmann WG, Kuehne ME, Glick SD (1992) Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Res 571:242–247
Gershon S, Lang WJL (1962) A psychopharmacological study of some indole alkaloids. Arch Int Pharmacodyn Ther 135:31–56
Gillan S, Kosterlitz HW (1982) Spectrum of the mu, delta, and kappa binding sites in homogenates of rat brain. Br J Pharmacol 77:461–469
Glick SD, Rossman K, Steindork S, Maisonneuve IM, Carlson JN (1991) Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur J Pharmacol 195:341–345
Javitt DC, Zukin SR (1989) Bioexponential kinetics of [3H]MK801 binding: evidence for access to closed and openN-methyl-d-aspartate receptor channels. Mol Pharmacol. 35:387–393
Kolesnikov Y, Ferkany J, Pasternak G (1994a) Blockade of mu and kappa opioid analgesic tolerance by NPC 17740, a novel NMDA antagonist. Life Sci (in press)
Kolesnikov Y, Maccehini ML, Pasternak G (1994b) Amino cyclopropyl caboxylic acid (ACPC) prevents mu and delta opioid tolerance. Life Sci (in press)
Lacosta S, Roberts DC (1992) MDL 72222, ketanserin, and methysergide pretreatments fail to alter breaking points on a progressive ratio schedule reinforced by intrvenous cocaine. Pharmacol Biochem Behav 44:161–165
Lahti RA, Mickelson MM, McCall JM, Von Voightlander PM (1985) [3H]U-69593: a highly selective ligand for the opioid kappa receptor. Eur J Pharmacol 109:281–284
Lane JD, Pickering CL, Hooper ML, Fagan K, Tyers MB, Emmett-Oglesby MW (1992) Failure of ondansetron to block the discriminative or reinforcing stimulus effects of cocaine in the rat. Drug Alcohol Depend 30:151–162
Leysen JE, Niemegeers CJE, Van Nueten JM, Laduron PM (1982) [3H]Ketanserin: a selective tritiated ligand for serotonin2 receptor binding sites. Mol Pharmacol 21:301–314
Lummins SCR, Kilpatrick GJ, Martin IL (1990) Characterization of 5HT3 receptors in intact N1E-115 neuroblastoma cells. Eur J Pharmacol 189:223–227
Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA (1989) Cocaine receptors labeled by [3H]-2-beta-carbomethoxy-3-beta-(4-fluorophenyl). Mol Pharmacol 36:518–524
Maisonneuve IM, Glick SD, Keller RW, Glick SD (1991) Interactions between ibogaine, a potential antiaddictive agent, and morphine: an in vivo microdialysis study. Eur J Pharmacol 199:35–42
Maisonneuve IM, Rossman KL, Keller RW, Glick SD (1992) Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats. Brain Res 575:69–73
Mello NK, Mendelson JH, Bree MP, Lukas SE (1989) Buprenorphine suppresses cocaine self-administration by Rhesus monkeys. Science 245:869–862
Montgomery AM, Rose IC, Herberg LJ (1993) The effect of a 5-HT3 receptor antagonist, ondansteron, on brain stimulation reward, and its interaction with direct and indirect stimulants of central dopaminergic transmission. J Neural Transm [Gen Sect] 91:1–11
Naranjo C (1969) Psychotropic properties of the harmala alkaloids. In: Efron D, Holmstedt B, Kline N (eds) Ethanopharmacologic search for psychoactive drugs. Raven, New York, pp 385–396
Nestler EJ, Hyman S (1993) The molecular foundations of psychiatry. American Psychiatric Press, Washington DC
O'Hearn E, Molliver ME (1993) Degeneration of Purkinje cells in the parasagittal zones of the cerebral vermis after treatment with ibogaine or harmaline. Neuroscience 55:303–310
O'Hearn E, Long DB, Molliver ME (1993) Ibogaine induces glial activation in parasagittal zones of the cerebellum. Neuroreport 4:299–302
Parsons LH, Schad CA, Justice JB Jr (1993) Co-administration of the D2 antagonist pimozide inhibits up-regulation of dopamine release and uptake induced by repeated cocaine administration. J Neurochem 60:376–379
Popik P, Thayer TL, Skolnick P (1994) The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex. Psychopharmacology 114:672–674
Pourgash S, Riley AL (1993) Buprenorphine as a stimulus in drug discrimation learning: an assessment of mu and kappa receptor activity. Pharmacol Biochem Behav 46:593–604
Raisman R, Sette M, Pimoule C, Briley M, Langer SZ (1982) High affinity [3H]desipramine binding in the peripheral and central nervous system: a specific site association with the neuronal uptake of noradrenaline. Eur J Pharmacol 78:345–351
Rasmussen K, Fuller RW, Stockton ME, Perry KW, Swinford RM, Ornstein PL (1991) NMDA receptor antagonists suppress behavior but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. Eur J Pharmacol 197:9–16
Repke D, Artis D, Nelson J, Wong EHZ (1994) Abbreviated ibogaine congeners. Synthesis and reactions of tropan-3-yl-2- and -3-indoles. Investigations of an unusual isomerization of 2-substituted indoles using computational and spectroscopic techniques. J Org Chem 59:2164–2171
Richards MH (1990) Rat hippocampal muscarinic autoreceptors are similar to the M2 (cardiac) subtype: comparison with hippocampal M1, atrial M2, and ileal M3. Br J Pharmacol 99:753–761
Ritz MC, George FR (1993) Cocaine-induced siezures and lethality appear to be associated with distinct central nervous system binding sites. J Pharmacol Exp Ther 263:1333–1343
Schneider JA, Sigg EB (1957) Neuropharmacological studies on ibogaine, an indole alkaloid with central stimulant properties. Ann NY Acad Sci 66:765–766
Sershen H, Hashim A, Harsing L, Lajtha A (1992) Ibogaine antagonizes cocaine-induced locomotor stimulation in mice. Life Sci 50:1079–1086
Slovatik RS, Drust EG, Damiano BP, Connor JD (1987) A common mechanism for lysergic acid, indolealkylamine and phenethylamine hallucinogens: serotonergic mediation of behavioral effects in rats. J Pharmacol Exp Ther 214:231–238
Svingos AL, Hitzman R (1992) 5-HT3 receptor antagonists block cocaine-induced locomotion via a PCPA-sensitive mechanism. Pharmacol Biochem Behav 43:871–879
Sweetnam P, Caldwell L, Lancaster J, Bauer C, McMillan B, Kinnier WJ, Price CH (1993) The role of receptor binding in drug discovery. J Nat Prod 56:441–455
Sweetnam P, Price CH, Ferkany J (1994) Mass ligand screening as a tool for drug discovery and development. In: Wolf ME (ed) Burger's Medicinal chemistry and drug discovery. Wiley, New York
Timmermans PBMWM, Karamatali F, Kwa HY, Schoop AMY, Slothorst-Grispijr FP, Van Zwieten PH (1981) Identical antagonist selectivity of central and peripheral alphal-adrenoreceptors. Mol Pharmacol 20:295–301
Tiseo PJ, Inturrisi CE (1992) Attenuation and reversal of morphine tolerance by the competitiveN-methyld-aspartate receptor antagonist, LY274614. J Pharmacol Exp Ther 264:1090–1096
Trouvin JH, Jacqumin P, Rouch C, Lesne M, Jacquot C (1987) Benzodiazepine receptors are involved in tabernanthine-induced tremor: in vitro and in vivo evidence. Eur J Pharmacol 140:303–307
Trujillo KA, Akil H (1991) Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251:85–85
Vignon J, Chicheportiche R, Chicheportiche M, Kamenka J-M, Geneste P, Lazdunski M (1983) [3H]TCP: a new tool with high affinity to the PCP receptor in rat brain. Brain Res 280:194–196
Watson M, Yamamura HI, Roeske WR (1986) [3H]Pirenzepine and [3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic and cholenergic sites: characterization and regulation of antagonist binding to putatiave muscarinic subtypes. J Pharmacol Exp Ther 237:411–427
Weber E, Sonder M, Quaram M, McLean S, Pou S, Keana JF (1986) [3H]Di(2-tolyl)quanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc Natl Acad Sci USA 83:8784–8788
Whitaker PM, Seeman P (1977) Hallucinogen binding to dopamine/neuroleptic receptors. J Pharm Pharmacol 29:506–507
Zetler G, Singbartl G, Schlosser L (1972) Cerebral pharmacokinetics of tremor-producing harmala and iboga alkaloids. Pharmacology 7:237–248
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sweetnam, P.M., Lancaster, J., Snowman, A. et al. Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity. Psychopharmacology 118, 369–376 (1995). https://doi.org/10.1007/BF02245936
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245936